CAR-T cells: the long and winding road to solid tumors.
D'Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. · 2018
Read CAR-T cells: the long and winding road to solid tumors. by D'Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5833816.txt.
Introduction
D'Aloia and co-authors trace why CAR-T cell therapy, a star in blood cancers, stalls in solid tumors. Their review appeared in Cell Death & Disease. The engineered cells must reach the tumor and survive there. Solid tumors guard themselves with a hostile neighborhood.
The roadblocks stack up along the way. Cells get lost, tire out, or meet suppressive stroma. Tumors shed the target antigen and slip away. Safety risks shadow every gain in power. The authors survey fixes, from safer gene delivery to genome editing. They also weigh transposon systems that plant the receptor without viruses.
Catalog record
| CREATOR | D'Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
CAR-T cells: the long and winding road to solid tumors By Maria Michela D’Aloia, Ilaria Grazia Zizzari, Benedetto Sacchetti, Luca Pierelli, Maurizio Alimandi Published in: Cell Death & Disease DOI: 10.1038/s41419-018-0278-6 ABSTRACT Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the “next generation” of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment surrounding the neoplastic foci. The intricate net of cross-interactions occurring between tumor components, stromal and immune cells leads to an ineffective anergic status favoring the evasion from the host’s defenses. Our goal is hereby to trace the road imposed by solid tumors to CAR-T cells, highlighting pitfalls and strategies to be developed and refined to possibly overcome these hurdles. FACTS Unparalleled clinical efficacy has been demonstrated using anti CD19-CAR-T cells to treat refractory B-cell malignancies.Many are the challenges imposed by solid tumors for a successful development of CAR T-cell immunotherapy.Genetically modified T cells can be alternatively generated using transposons systems (e.g., Sleeping Beauty) to stably introduce CARs in T lymphocytes. OPEN QUESTIONS How CARs should be designed and engineered to be effective in the treatment of solid tumors?Which strategies need to be developed and refined to improve the balance between favorable and unfavorable effects for better therapeutic benefits?What are the priorities for CAR-T cell therapy that must be addressed as they concern safety and efficacy?Can the use of genome editing techniques be helpful in generating CAR-armed T lymphocytes suitable for the treatment of solid tumors? INTRODUCTION T cells normally build poor or no response against syngeneic transformed cells, (a) for their poor antigenicity, (b) because transformed cells are not phenotypically foreign, and (c) for the generalized immunosuppressive conditions often associated with cancer. For these reasons, adequate immune responses against tumors have seldom been observed, at least in patients treated with chemotherapeutic agents1,2. These observations stimulated oncologist and immunologists to boost and activate the T-cell responses against tumor cells, attempts that over the years, never accomplished straightforward clinical results. Recent knowledge shows that the immune system is kept in shape through a delicate network of signaling pathways delivered by T-cell activating receptors (accelerators) and inhibitory receptors (brakes) to regulate the balance between immune response and immune tolerance3–5. This established the platform for developing the “alternative strategy” aimed to take the brakes off the anti-tumor immune responses. The successful use of immune-checkpoint inhibitors in clinical trials highlights the enormous potentials of the immune system to efficiently react against virtually any kind of tumor cell. The advantages in terms of significant antitumor activity, induction of long-lasting responses, and favorable safety profile obtained with the use of checkpoint inhibitors (anti-PD-1/PD-L1 antibodies and anti-CTLA-4), definitely proved the concept that the immune cellular responses may be pivotal to regulate anti-cancer activities6,7. Together with the check inhibition, the adoptive cell therapy (ACT) with chimeric antigen receptor (CAR) redirected T cells is perhaps the most attractive anti-cancer strategy. CARs encode for transmembrane chimeric molecules with dual function: (a) immune recognition of tumor antigens expressed on the surface of tumor cells; (b) active promotion and propagation of signaling events controlling the activation of the lytic machinery. This system has several advantages: (1) to provide “reprogrammed T-cells” of an ex-novo activation mechanism; (2) to brake the tolerance acquired by tumor cells, and (3) bypass restrictions of the HLA-mediated antigen recognition, over-stepping one of the barriers to a more widespread application of cellular immunotherapy8. Eshhar and coworkers were the first to demonstrate that linking the scFv with the TCR ζ-chain or γ-chain for signal transduction, provides T lymphocytes with Ab-type specificity and activates all the functions of an effector cell, including the production of IL-2 and the lysis of target cells9. Since then, efforts have been dedicated to produce a number of CARs designed to implement quality, strength and duration of signals delivered by the chimeric molecules. Variability in the functional properties has been obtained by engineering CARs expressing the ζ-chain alone (1st generation) or in tandem with the CD28 (2nd generation), or variably combined with a third signaling domain (3rd generation), such as the 4-1BB (CD137), the OX40 (CD134), ICOS and CD27, with the idea to enhances T-cell proliferation, IL-2 secretion, survival and cytolytic activity. The 4th generation includes “Armored CARs”, designed to increase persistence of engineered T cells in tumor’s microenvironment. Armored CARs combine the CAR functional activities with the secretion of IL-2 or IL-12 expressed as an independent gene in the same CAR vector10–18 (Fig.1).Fig. 1Schematic representation of the chimeric antigen receptors for adoptive cell therapy.CARs comprise an extracellular domain with a tumor-binding moiety, typically a single-chain variable fragment (scFv), followed by a hinge/spacer of varying length and flexibility, a transmembrane (TM) region, and one or more signaling domains associated with the T-cell signaling. The 1st CARs generation is equipped with the stimulatory domain of the ζ-chain; in the 2nd CARs generation the presence of costimulatory domains (CD28) provides additional signals to ensure full activation; in the 3rd generation an additional transducer domain (CD27, 41-BB or OX40) is added to the ζ-chain and CD28 to maximize strength, potency, and duration of the delivered signals; the 4th generation includes armored CARs, engineered to synthetize and deliver interleukins (green ovals) Although the initial attempts to treat patients affected by a variety of solid and liquid tumors, the breakthrough with CAR-T cells therapy was achieved targeting B-cell hematologic tumors. The use of anti-CD19 CAR T cells have demonstrated consistently high antitumor efficacy in children and adults affected by relapsed B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia, and B-cell non-Hodgkin lymphoma, with percentage of complete remissions ranging from 70 to 94% in the different trials19. Based on these results, the FDA has approved two immunotherapies with anti-CD19 modified T cells, KYMRIAH [tisagenlecleucel (August 2017)] and YESCARTA [axicabtagene ciloleucel (October 2017)]. These are now a second line treatment for patients up to 25 years of age with B-ALL (KYMRIAH) and for adults with certain types of large B-cell lymphoma (YESCARTA). Similar for the presence of an anti-CD19 murine scFv, they signal through a different costimulatory domain fused in tandem with the CD3 ζ-chain: 4-1BB for KYMRIAH, and CD28 for YESCARTA. Other B-cell antigens have been targeted in preclinical models, including CD20, CD22, CD23, ROR1, and the kappa light chain. In principle, the treatment of B-cell malignancies with CAR-T cells leads to almost entire B cells repertoire depletion. In this case, the problems derived by the disappearance of B cells from blood can be partially mitigated by immunoglobulins administration. However, depletion of other cell lineages might not be as manageable, and the use of CAR-T cell therapies might be restricted only to specific hematopoietic lineages. In addition, large tumor masses clearance observed in these trials was accompanied by acute and often severe syndrome requiring intensive care, following massive release of cytokines from on-target activated T cells20–22. CAR-T CELLS THERAPY FOR SOLID TUMORS Less exciting conclusions can be derived from clinical trials designed for the treatment of solid tumors with engrafted CAR-T lymphocytes. Although from most of the trials we do not have yet evaluable data, there is enough proof to establish a solid platform for development of CAR-T cells therapy for